Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 31, Number 6—June 2025

Research

Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia

Ivan O. RosasComments to Author , Alejandra Benitez, James A. McKinnell, Reena Shah, Michael Waters, Bradley D. Hunter, Robert Jeanfreau, Larry Tsai, Margaret Neighbors, Ben Trzaskoma, Rita de Cassia Castro, and Fang Cai
Author affiliation: Baylor College of Medicine, Houston, Texas, USA (I.O. Rosas); Genentech, South San Francisco, California, USA (A. Benitez, L. Tsai, M. Neighbors, B. Trzaskoma, R. de Cassia Castro, F. Cai); Torrance Memorial Medical Center, Torrance, California, USA (J.A. McKinnell); Aga Khan University Hospital, Nairobi, Kenya (R. Shah); Velocity Clinical Research, Chula Vista, California, USA (M. Waters); Intermountain Healthcare, Salt Lake City, Utah, USA (B.D. Hunter); Velocity Clinical Research, New Orleans, Louisiana, USA (R. Jeanfreau)

Main Article

Figure 3

Numbers of participants with >1 lung texture abnormality at baseline and at month 12 in study of long-term clinical outcomes of adults hospitalized for COVID-19 pneumonia. Data are shown for a total of 173 participants enrolled in the Long-Term Outcomes Post Acute COVID-19 study. Colors indicate whether the lung texture abnormality was present or absent. Baseline and month 12 columns indicate the no. (%) participants who had >1 lung texture abnormality at that time point. Numbers between those columns indicate lung abnormalities that persisted, developed, or resolved by month 12.

Figure 3. Numbers of participants with >1 lung texture abnormality at baseline and at month 12 in study of long-term clinical outcomes of adults hospitalized for COVID-19 pneumonia. Data are shown for a total of 173 participants enrolled in the Long-Term Outcomes Post Acute COVID-19 study. Colors indicate whether the lung texture abnormality was present or absent. Baseline and month 12 columns indicate the no. (%) participants who had >1 lung texture abnormality at that time point. Numbers between those columns indicate lung abnormalities that persisted, developed, or resolved by month 12.

Main Article

Page created: March 24, 2025
Page updated: June 09, 2025
Page reviewed: June 09, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external